135598-68-4

Basic information

• Product Name: CNDAC
• Synonyms: 4-Amino-1-(2-cyano-2-deoxy-beta-D-arabinofuranosyl)-2(1H)-pyrimidinone
• CAS NO: 135598-68-4
• Molecular Formula: C₁₀H₁₂N₄O₄
• Molecular Weight: 252.22668
• EINECS: -0
• Mol File: 135598-68-4.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 596.9±60.0 °C(Predicted)
• Appearance: /
• Density: 1.75±0.1 g/cm3(Predicted)
• PKA: 12.78±0.70(Predicted)
• CAS DataBase Reference: CNDAC(CAS DataBase Reference)
• NIST Chemistry Reference: CNDAC(135598-68-4)
• EPA Substance Registry System: CNDAC(135598-68-4)

Safety Data

• Hazardous Substances Data: 135598-68-4(Hazardous Substances Data)

Usage

General Description

CNDAC, also known as 2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosylcytosine, is a synthetic nucleoside analog that has been investigated for its potential use in the treatment of cancer. The chemical is a cytidine analog and acts as a potent inhibitor of DNA polymerase, which is involved in the replication of cancer cells. CNDAC has shown promising anti-cancer activity in preclinical studies, and its ability to inhibit DNA synthesis makes it a potential candidate for the treatment of various types of cancer. Additionally, CNDAC has been studied for its potential in combination therapy with other anti-cancer agents, with encouraging results. Research on CNDAC continues to explore its potential as a novel and effective treatment for cancer.

Upstream product

• 135598-72-0 N⁴-acetyl-1-(2-C-cyano-2-deoxy-β-D-arabinofuranosyl)cytosine 
• 135598-71-9 N⁴-acetyl-1-<2-C-cyano-2-deoxy-3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-arabinofuranosyl>cytosine 
• 140859-16-1 N⁴-acetyl-1-<3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-erythro-pentofuran-2-ulosyl>cytosine 
• 134665-72-8 2'-C-cyano-2'-deoxy-1-β-D-arabinofuranosylcytosine hydrochloride 

Downstream Products

• 151823-14-2 sapacitabine 
• 71-30-7 Cytosine 

Relevant articles and documents

PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHEIS OF 2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYLCYTOSINE

The present invention relates to a process for preparing a compound of formula 682-4, said process comprising the steps of: (i) converting a compound of formula 682-1 into a compound of formula 682-2'; (ii) converting said compound of formula 682-2' into a compound of formula 682-3; and (iii) converting said compound of formula 682-3 into a compound of formula 682-4. Further aspects of the invention relate to the use of the above process in the preparation of 2'-cyano-2'-deoxy-N4 -palmitoyl-1-β-D-arabmofuranosylcytosine, a pyrimidine nucleoside which is therapeutically useful in the treatment and/or prevention of cancer.

CRYSTALLINE PYRIMIDINE NUCLEOSIDE DERIVATIVE SUSPENSIONS IN CAPSULES

The present invention relates to a pharmaceutical formulation which comprises (i) a capsule, and (ii) a core comprising crystalline 2′-cyano-2′-deoxy-N4-palmitoyl-1-β-D-arabinofuranosylcytosine and a liquid carrier.

Nucleosides and nucleotides. 100. 2'-C-cyano-2'-deoxy-1-β-D-arabinofuranosyl-cytosine (CNDAC): Design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside [1]

-